EUVIMEDEUVIMED entdecken
Scoping ReviewStudienprotokollOpen Access

Risk-of-Bias Assessment of Target Trial Emulation Studies at Regulatory and Policy Decision Points Along the Medical Product Life Cycle: Protocol for a Scoping Review and Stakeholder Survey

Anni Kokolahti iD, Saara Puustinen iD, Martin Russek iD, Christoph Röthlein iD, Cornelia Becker iD, Jonas Peltner iD, Ines Costa iD, Sirpa Hartikainen iD, Britta Haenisch iD, Cláudia Furtado iD, Anna-Maija Tolppanen iD, Christina Tikka iD

JMIR Research Protocols · 2026

DOI: 10.2196/107499 ↗

Kurz gefasst

Scoping Review in der Zeitschrift JMIR Research Protocols, 2026. Verfasst von Anni Kokolahti und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Policy Making. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Target trial emulation (TTE) studies are increasingly important for regulatory decision‑making and health technology assessments (HTAs), but current risk-of-bias (RoB) tools are not specifically tailored to assess biases central to TTE studies—such as immortal time bias, misaligned eligibility criteria, and prevalent user bias. RoB assessment for TTE studies thus remains difficult, and it is unclear which tools and adaptations researchers currently use or how well they work.

Objective

This study aims to analyze the RoB assessment of TTE studies at regulatory and policy decision points along the medical product life cycle by providing a systematic overview of tools developed, used, adapted, or evaluated for TTE studies and the perceived importance and feasibility of assessing TTE studies by HTA assessors, regulators, systematic reviewers, and methods experts.

Methods

This is a protocol for a scoping review and online survey among systematic reviewers, methods experts, European HTA organizations, and regulators. We will collect data on the name, description, and feasibility of RoB tools used, adapted, and developed for TTE studies, as well as RoB assessment results and the RoB sources relevant for TTE studies. Two authors will use qualitative content analysis to analyze the data independently. The systematic search for published and gray literature in 4 electronic databases (PubMed, Scopus, Web of Science, and the Cochrane Library), on relevant websites (eg, Cochrane, HTA and regulatory agencies), and through reference list checking was conducted in May to June 2026.

Results

As of August 25, 2026, screening is ongoing, and 78 references have been preliminarily included in the scoping review. We will analyze the scoping review and survey data and provide an overview of the types, feasibility, and assessment results of RoB tools currently used, adapted, or developed for TTE studies, as well as the RoB sources considered relevant for TTE studies by HTA assessors, regulators, systematic reviewers, and methods experts. Analysis results of the literature review and survey are expected in September 2026 and November 2026, respectively.

Conclusions

The analysis of the scoping review and survey data will inform users of TTE evidence about the feasibility of RoB tools; future development and training needs; and the perceived value of assessing the RoB in HTAs, regulatory decisions, and systematic reviews. International Registered Report Identifier (IRRID) DERR1-10.2196/107499

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalPolicy MakingHumansScoping Reviews as TopicBiasSurveys and QuestionnairesResearch DesignRisk AssessmentDecision MakingStakeholder Participation

Stichwörter der Autor:innen

health technology assessmentreal-world evidenceregulatory decision-makingrisk of biasscoping reviewstakeholder surveytarget trial emulation

Autor:innen und Institutionen

  • School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
  • Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.
  • Portuguese National Authority of Medicines and Health Products (Infarmed), Lisbon, Portugal.
  • German Center for Neurodegenerative Diseases, Bonn, Germany.
  • Center for Translational Medicine, University of Bonn, Bonn, Germany.
  • NOVA National School of Public Health, NOVA University Lisbon, Lisbon, Portugal.

ORCID-Profile: Anni Kokolahti, Saara Puustinen, Martin Russek, Christoph Röthlein, Cornelia Becker, Jonas Peltner, Ines Costa, Sirpa Hartikainen, Britta Haenisch, Cláudia Furtado, Anna-Maija Tolppanen, Christina Tikka

Zitieren

APA

Kokolahti, A., Puustinen, S., Russek, M., Röthlein, C., Becker, C., Peltner, J., Costa, I., Hartikainen, S., Haenisch, B., Furtado, C., Tolppanen, A. M., & Tikka, C. (2026). Risk-of-Bias Assessment of Target Trial Emulation Studies at Regulatory and Policy Decision Points Along the Medical Product Life Cycle: Protocol for a Scoping Review and Stakeholder Survey. JMIR Research Protocols. https://doi.org/10.2196/107499

Vancouver

Kokolahti A, Puustinen S, Russek M, Röthlein C, Becker C, Peltner J, et al. Risk-of-Bias Assessment of Target Trial Emulation Studies at Regulatory and Policy Decision Points Along the Medical Product Life Cycle: Protocol for a Scoping Review and Stakeholder Survey. JMIR Research Protocols. 2026. doi:10.2196/107499

BibTeX
@article{Kokolahti2026,
  author = {Kokolahti, Anni and Puustinen, Saara and Russek, Martin and Röthlein, Christoph and Becker, Cornelia and Peltner, Jonas and Costa, Ines and Hartikainen, Sirpa and Haenisch, Britta and Furtado, Cláudia and Tolppanen, Anna-Maija and Tikka, Christina},
  title = {Risk-of-Bias Assessment of Target Trial Emulation Studies at Regulatory and Policy Decision Points Along the Medical Product Life Cycle: Protocol for a Scoping Review and Stakeholder Survey},
  journal = {JMIR Research Protocols},
  year = {2026},
  doi = {10.2196/107499}
}
Kostenlos starten →